☆ 4.1 Article

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States

JOURNAL OF MEDICAL ECONOMICS (2012)

Get Full Text
Add to Collection

Journal

JOURNAL OF MEDICAL ECONOMICS
Volume 15, Issue 4, Pages 654-663

Publisher

Informa Healthcare
DOI: 10.3111/13696998.2012.670677

Keywords

-

Categories

Medicine, General & Internal

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.